Plant Name: Disynaphia halimifolia
Taxonomic Information:
Plant ID: NPO29047
Plant Latin Name: Disynaphia halimifolia
Taxonomy Genus: Disynaphia
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR4; FFAR1; | |
| NPSR1; | |
| ALPL; ALOX12; HSD17B2; HSD17B10; ALOX15; NOX4; APEX1; POLB; | |
| ACHE; | |
| BCL2; | |
| CDK6; PIM1; MET; AXL; PRKCA; FLT3; CDK1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA1; CA14; CA7; | |
| PPARA; | |
| NR1H4; | |
| TYR; | |
| KDM4E; | |
| F10; | |
| AHR; NFKB1; | |
| FUT7; | |
| SLCO1B1; | |
| LMNA; FABP3; FABP5; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.432E-10 | 5.196E-07 | CA1, CA12, CA14, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 3.409E-08 | 2.855E-05 | ALOX12, AURKB, AXL, BCL2, CDK1, FFAR4, IGF1R, KDR, LMNA, NFKB1, NR1H4, PIM1, PRKCA |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.931E-08 | 3.472E-05 | CA1, CA12, CA14, CA2, CA7 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 1.640E-07 | 8.929E-05 | ACHE, CYP1A1, CYP1B1, FFAR1, FFAR4, HSD17B2, NFKB1, NR1H4, PRKCA, SLCO1B1 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 3.955E-07 | 1.758E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 8.855E-07 | 3.268E-04 | ALOX12, BCL2, CA12, CA2, CA7, FABP3, FABP4, FFAR1, MET, NOX4, NPSR1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.308E-06 | 4.130E-04 | CA1, CA12, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.309E-06 | 4.130E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.758E-06 | 5.172E-04 | ALPL, APEX1, BCL2, CA2, CYP1A2, FABP3, FFAR4, FLT3, NFKB1, PPARA |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 3.069E-06 | 8.535E-04 | ACHE, ALOX15, BCL2, CDK1, CYP1A1, PPARA |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.259E-06 | 8.654E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 3.858E-06 | 9.883E-04 | ALOX12, ALOX15, APEX1, CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, KDM4E, NOX4, TYR |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.071E-06 | 1.175E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.071E-06 | 1.175E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.071E-06 | 1.175E-03 | ALOX12, ALOX15 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 6.070E-06 | 1.391E-03 | ALOX12, BCL2, F10, IGF1R, KDR, MET, NOX4, PRKCA |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 7.333E-06 | 1.613E-03 | AURKB, CDK1, PRKCA |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 9.727E-06 | 2.037E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.112E-05 | 2.262E-03 | APEX1, AXL, CDK1, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.324E-05 | 2.598E-03 | ALPL, APEX1, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.425E-05 | 2.746E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.519E-05 | 2.803E-03 | CA2, CA7 |
| BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 1.519E-05 | 2.803E-03 | BCL2, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.519E-05 | 2.803E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.519E-05 | 2.803E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.892E-05 | 3.349E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.892E-05 | 3.349E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.449E-05 | 4.232E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.034E-05 | 5.082E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.064E-05 | 5.093E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 3.472E-05 | 5.727E-03 | AURKB, CDK1, PRKCA |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 3.680E-05 | 6.025E-03 | ALPL, AXL, CYP1A1, CYP1A2, NFKB1, NR1H4 |
| MF | GO:0005488; binding | GO:0008134; transcription factor binding | 4.850E-05 | 7.233E-03 | AHR, APEX1, BCL2, FLT3, NFKB1, NR1H4, PIM1, PPARA |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 5.049E-05 | 7.330E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 6.283E-05 | 8.770E-03 | AXL, FLT3, IGF1R, KDR, MET |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.473E-10 | 3.758E-08 | CA12, CA1, CA2, CA7, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.358E-06 | 2.208E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.551E-06 | 2.208E-04 | CDK6, PIM1, BCL2, CYP1B1, PRKCA, MET, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 8.776E-06 | 2.668E-04 | CDK6, KDR, BCL2, PRKCA, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.343E-05 | 5.087E-04 | CDK6, FLT3, BCL2, PRKCA, MET, NFKB1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.926E-06 | 2.668E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 7.121E-05 | 1.199E-03 | PIM1, BCL2, PRKCA, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.587E-05 | 4.020E-04 | FABP3, FABP4, FABP5, PPARA |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 7.887E-05 | 1.199E-03 | KDR, BCL2, PRKCA, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.687E-05 | 1.199E-03 | BCL2, PRKCA, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.365E-04 | 1.729E-03 | KDR, PRKCA, MET, NFKB1, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.273E-05 | 1.281E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.948E-04 | 3.201E-03 | CDK6, BCL2, PRKCA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.675E-04 | 3.128E-03 | FLT3, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 3.945E-04 | 3.998E-03 | CDK6, PRKCA, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 5.115E-04 | 4.573E-03 | CDK6, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.018E-03 | 6.686E-03 | KDR, PRKCA, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 6.503E-04 | 5.203E-03 | FLT3, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.056E-03 | 6.686E-03 | POLB, CDK6, CDK1, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.549E-04 | 4.686E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 9.887E-04 | 6.686E-03 | BCL2, NFKB1, IGF1R |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 5.115E-04 | 4.573E-03 | SLCO1B1, CA2, NR1H4 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.290E-03 | 7.539E-03 | FUT7, HSD17B2, CYP1A2, ALOX15, CYP1A1, ALPL, ALOX12, TYR, HSD17B10 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.175E-03 | 7.142E-03 | KDR, PRKCA, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 8.951E-04 | 6.479E-03 | CDK6, BCL2, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.793E-04 | 5.923E-03 | CYP1A2, CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; |
| NA: NA | Haemophilia B | NA | F10; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Christmas disease | NA | F10; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; CA1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; BCL2; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; CA1; BCL2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; BCL2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; BCL2; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; BCL2; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
